Discount contracts for Darbepoetin alfa for German statutory health insurance.
The procurement concerns the conclusion of discount contracts for the biologic Darbepoetin alfa, covering various pharmaceutical forms and dosages. The buyer is a German health insurance association (or similar) serving statutory health insurance funds. Bidders must be pharmaceutical manufacturers with authorization to market Darbepoetin alfa in Germany. The contract duration is implied to be multi-year, starting in 2026. The scale is national, covering the entire German statutory health insurance market.